Prophylactic use of myelopoietic growth factors in children after myelosuppressive chemotherapy: does it pay?
Bessmertny
Olga
O
Department of Pharmacy, Children's Hospital of New York Presbyterian, Columbia University, New York 10032, USA.
Cairo
Mitchell S
MS
D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D003362:Cost-Benefit Analysis; D017850:Economics, Pharmaceutical; D016179:Granulocyte Colony-Stimulating Factor / Q000191:economics / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy / Q000191:economics / Q000628:therapy*; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control*
D000970:Antineoplastic Agents; D016179:Granulocyte Colony-Stimulating Factor